65,437 trials
Advanced Adult Hepatocellular Carcinoma · Non-Resectable Hepatocellular Carcinoma
Primary: PFS, Assessed Using Standard RECIST Criteria — 58 percentage of participants
Breast Cancer
Primary: Rate of Clinical Benefit — 0; 0; 6; 11 Participants
Coronary Stenosis
Primary: Primary Endpoint: Device Success — 44 Participants
Heterozygous Familial Hypercholesterolemia · Elevated Cholesterol
Primary: Percent Change in LDL-C From Baseline To Day 510 — -41.15; 8.37 percent change — p=<.0001
Oxygen Consumption
Primary: Oxygen Consumption — .28; .27 mls/kg/min
Peripheral Arterial Diseases
Primary: Percent Change From Baseline in Initial Claudication Distance (ICD) at Week 12 — 21.99; 51.17 percent change — p=0.0041
Pruritus · Prurigo Nodularis
Primary: Percent of Participants With Worst Itch Numeric Rating Scale (WI-NRS) 4-point Responder Rate at Week 10 — 18.95; 25.90; 81.05; 74.10 Percentage of participants — p=0.158
Urinary Tract Infections
Primary: Resolution of UTI Symptoms 14 Days After Completing Active Antimicrobial Therapy — 111; 122 Participants
Rhinosinusitis
Primary: Sino-Nasal Outcomes Test — 2.3; 1.1 score on a scale — p=<0.0001
Radial Artery Spasm · Angina · Coronary Artery Disease
Primary: Radial Artery Spasm — 8; 15 Participants
Acute Unilateral Vestibulopathy (AUV)
Primary: Standing Vertigo Intensity — 165.10; 155.10; 136.60 mm*day — p=0.8466
Allergic Conjunctivitis
Primary: Ocular Itching — 0.43; 0.40; 1.60; 1.81 score on a scale
Asthma in Children
Primary: Acceptability Using Semi Structured Questionnaires in Focus Groups and Interviews — 7; 4; 3 Participants
Allergic Conjunctivitis
Primary: Ocular Itching — 0.50; 0.49; 1.87; 1.93 score on a scale
Myopia
Primary: Subjective Ratings of Comfort — 92; 91 units on a scale